JOP20200156A1 - إيسكيتامين لعلاج الاكتئاب - Google Patents

إيسكيتامين لعلاج الاكتئاب

Info

Publication number
JOP20200156A1
JOP20200156A1 JOP/2020/0156A JOP20200156A JOP20200156A1 JO P20200156 A1 JOP20200156 A1 JO P20200156A1 JO P20200156 A JOP20200156 A JO P20200156A JO P20200156 A1 JOP20200156 A1 JO P20200156A1
Authority
JO
Jordan
Prior art keywords
depression
esketamine
treatment
patient
effective amount
Prior art date
Application number
JOP/2020/0156A
Other languages
English (en)
Inventor
Carla Canuso
Ewa Wajs
Jaskaran Singh
David Wood Hough
Rachel Ochs-Ross
Wayne Drevets
Honglan Li
Peter Zannikos
Adam Janik
Ella Daly
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20200156A1 publication Critical patent/JOP20200156A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي طرقًا للحفاظ على هدأة أو استجابة مستقرة من جانب مريض يعاني من الاكتئاب بعد إعطاء كمية فعالة علاجيًا من إيسكيتامين خلال مرحلة الإعطاء الأولي، وتتألف من الاستمرار في إعطاء كمية فعالة علاجيًا من إيسكيتامين لمدة خمسة أشهر على الأقل خلال مرحلة الإعطاء اللاحق. ويوفر الاختراع الحالي أيضًا طرقًا للعلاج طويل الأجل للاكتئاب لدى مريض، وتتألف من إعطاء المريض الذي يحتاج إلى العلاج كمية فعالة علاجيًا من إيسكيتامين ثبت طبيًا أنها آمنة وفعالة لمدة ستة أشهر على الأقل. وفي بعض النماذج التطبيقية، يكون الاكتئاب عبارة عن اضطراب اكتئابي كبير أو اكتئاب مقاوم للعلاج. الشكل 1
JOP/2020/0156A 2017-12-22 2018-12-18 إيسكيتامين لعلاج الاكتئاب JOP20200156A1 (ar)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762609504P 2017-12-22 2017-12-22
US201862663219P 2018-04-26 2018-04-26
US201862663206P 2018-04-26 2018-04-26
US201862667406P 2018-05-04 2018-05-04
US201862675846P 2018-05-24 2018-05-24
US201862755905P 2018-11-05 2018-11-05
PCT/US2018/066143 WO2019126108A1 (en) 2017-12-22 2018-12-18 Esketamine for the treatment of depression

Publications (1)

Publication Number Publication Date
JOP20200156A1 true JOP20200156A1 (ar) 2022-10-30

Family

ID=65003585

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0156A JOP20200156A1 (ar) 2017-12-22 2018-12-18 إيسكيتامين لعلاج الاكتئاب

Country Status (16)

Country Link
US (2) US11707440B2 (ar)
EP (1) EP3501542A1 (ar)
JP (2) JP2021506924A (ar)
KR (2) KR20200113197A (ar)
CN (2) CN117531017A (ar)
AU (1) AU2018282466A1 (ar)
BR (1) BR112020012473A2 (ar)
CA (1) CA3086478A1 (ar)
IL (1) IL275482A (ar)
JO (1) JOP20200156A1 (ar)
MA (1) MA47719A (ar)
MX (2) MX2020006650A (ar)
PH (1) PH12020500555A1 (ar)
SG (1) SG11202005896WA (ar)
TW (2) TW202415363A (ar)
WO (1) WO2019126108A1 (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102217616B1 (ko) 2013-03-15 2021-02-19 얀센 파마슈티카 엔.브이. S-케타민 하이드로클로라이드의 약제학적 조성물
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
KR20210028159A (ko) 2018-06-27 2021-03-11 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하는 방법
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
MA55218A (fr) 2019-03-05 2022-01-12 Janssen Pharmaceuticals Inc Eskétamine pour le traitement de la dépression
US20220151955A1 (en) * 2019-08-05 2022-05-19 The Ketamine Research Foundation Ketamine for the treatment of postpartum symptoms and disorders
JP2022546456A (ja) * 2019-08-28 2022-11-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド 自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
BR112022004497A2 (pt) * 2019-09-13 2022-05-31 Janssen Pharmaceuticals Inc Administração intranasal de escetamina
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
EP4084786A1 (en) 2019-12-30 2022-11-09 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
CA3199076A1 (en) * 2020-10-22 2022-04-28 Tonix Pharmaceuticals Holding Corp. Randomization honoring methods to assess the significance of interventions on outcomes in disorders
WO2024201274A1 (en) * 2023-03-24 2024-10-03 Janssen Pharmaceutica Nv Esketamine for use in the treatment of depression

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10025A (en) 1853-09-20 Improvement in turbines
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JPS632932A (ja) 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
DE4312016A1 (de) 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
WO1996025925A1 (en) 1995-02-24 1996-08-29 Weg Stuart L Nasal and ocular administration of ketamine to manage pain and for detoxification
JPH11511466A (ja) 1995-08-30 1999-10-05 スチュアート エル ウェグ 苦痛を管理しおよび薬物依存性を軽減するための、ケタミンの投与
FR2739294B1 (fr) 1995-09-29 1998-01-16 Lhd Lab Hygiene Dietetique Embout nasal de securite
DE19619665C2 (de) 1996-05-15 2001-03-08 Goedecke Ag Racemattrennung von Ketamin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
FR2764807B1 (fr) 1997-06-18 1999-08-20 Valois Sa Dispositif de distribution nasale d'un produit fluide ou pulverulent
JP4790123B2 (ja) 1998-07-24 2011-10-12 ヨー、セオ、ホン 胆汁酸を有する透明水溶液型製剤の調剤
US6599883B1 (en) 1998-10-30 2003-07-29 Nastech Pharmaceutical Company, Inc. Nasal delivery of xylitol
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6017961A (en) 1999-07-08 2000-01-25 Flores; John Anthony Ketamine and n-butyl-p-aminobezoate in PLO
EP1103256A1 (de) 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2001291159A1 (en) 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP2027854A1 (en) 2002-11-18 2009-02-25 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US8082173B2 (en) 2003-05-22 2011-12-20 Cecil Kost Drug sample fulfillment architecture
US20050095277A1 (en) 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
US20040265364A1 (en) 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20060223788A1 (en) 2005-03-29 2006-10-05 Cathcart Clifton H Analgesic composition for topical use
JP5026411B2 (ja) 2005-06-01 2012-09-12 エスエイチエル グループ エービー 薬物送達装置
US20060276550A1 (en) 2005-06-03 2006-12-07 Dileep Bhagwat Topical compositions of ketamine and butamben and methods of their use
EP2012762A4 (en) 2006-03-22 2010-03-10 Sinai School Medicine INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION
WO2007123945A2 (en) 2006-04-21 2007-11-01 Aradigm Corporation Mechanical single dose intrapulmonary drug delivery devices
KR20090029200A (ko) 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
US8710070B2 (en) 2008-03-27 2014-04-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
US20120225949A1 (en) 2009-08-14 2012-09-06 Demitri Papalos Compositions and methods for treating bipolar disorder
AR081931A1 (es) 2010-06-15 2012-10-31 Gruenenthal Gmbh Combinacion farmaceutica
US9073819B2 (en) 2011-06-30 2015-07-07 University Of South Florida Compositions, methods of use, and methods of treatment
WO2013056229A1 (en) 2011-10-14 2013-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
WO2013074676A2 (en) 2011-11-14 2013-05-23 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
US20130209585A1 (en) 2012-02-13 2013-08-15 Stanley Kim Topical NMDA Antagonist Formulations for the Treatment of Peripheral Neuropathy
MX2014010939A (es) 2012-03-12 2014-11-13 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
AU2016203771A1 (en) 2012-03-13 2016-06-23 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
WO2013149102A1 (en) 2012-03-30 2013-10-03 The General Hospital Corporation Compositions comprising scopolamine and ketamine in the treatment of depression
US20140079740A1 (en) 2012-08-02 2014-03-20 ClinPharm Support GmbH Oral transmucosal adminstration forms of s-ketamine
AU2013305580A1 (en) 2012-08-23 2015-04-09 Stuart L. Weg Anxiolytic composition, formulation and method of use
FR2994844B1 (fr) 2012-08-31 2015-01-02 Assist Publ Hopitaux De Paris Formulation gelifiante a base de ketamine
NZ619257A (en) 2012-10-08 2015-07-31 Auckland Uniservices Ltd Ketamine derivatives
ES2484068B1 (es) 2013-02-08 2015-04-16 Ana MÍNGUEZ MARTÍ Una composición farmacéutica que contiene ketamina y amitriptilina
NZ713300A (en) 2013-04-12 2020-05-29 Icahn School Med Mount Sinai Method for treating post-traumatic stress disorder
WO2015031410A1 (en) 2013-08-26 2015-03-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
RS62516B1 (sr) 2013-09-13 2021-11-30 Univ Chiba Nat Univ Corp Primena r-ketamina i njegove soli kao farmaceutskih proizvoda
CN103705909A (zh) 2013-12-16 2014-04-09 陈镜伊 一种无痛人流用药
WO2015101693A1 (es) 2013-12-31 2015-07-09 Servicio Andaluz De Salud Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas
WO2015108985A1 (en) 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
ES2743699T3 (es) 2014-04-17 2020-02-20 Develco Pharma Schweiz Ag Forma de dosificación oral de ketamina
AU2015257825B2 (en) 2014-05-04 2018-08-02 Firmenich Sa Flavored food and beverage products
FR3023188B1 (fr) 2014-07-04 2016-08-19 Aptar France Sas Dispositif de distribution de produit fluide.
JP6545788B2 (ja) 2014-08-13 2019-07-17 ヤンセン ファーマシューティカ エヌ．ベー． うつ病の治療方法
EP3193853A1 (en) 2014-09-15 2017-07-26 Janssen Pharmaceutica NV VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
EP3240422A1 (en) 2014-12-31 2017-11-08 Icahn School of Medicine at Mount Sinai Method of maintaining the anti-depressant effect of ketamine with lithium
CN104798728A (zh) 2015-05-08 2015-07-29 南京中医药大学 产后抑郁动物模型的建立方法及其应用
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US20180296478A1 (en) 2016-02-12 2018-10-18 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
US20180042936A1 (en) 2016-03-18 2018-02-15 Genomind, Inc. Maintenance therapy using tianeptine
CN117531017A (zh) 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮

Also Published As

Publication number Publication date
PH12020500555A1 (en) 2021-05-17
EP3501542A1 (en) 2019-06-26
MX2023012450A (es) 2023-10-31
CA3086478A1 (en) 2019-06-27
RU2020123893A (ru) 2022-01-24
SG11202005896WA (en) 2020-07-29
KR20240011237A (ko) 2024-01-25
MA47719A (fr) 2020-01-15
CN117531017A (zh) 2024-02-09
WO2019126108A1 (en) 2019-06-27
US20210386688A1 (en) 2021-12-16
KR20200113197A (ko) 2020-10-06
IL275482A (en) 2020-08-31
TW202415363A (zh) 2024-04-16
US11707440B2 (en) 2023-07-25
RU2020123893A3 (ar) 2022-04-29
JP2021506924A (ja) 2021-02-22
US20240000728A1 (en) 2024-01-04
BR112020012473A2 (pt) 2020-11-24
TWI843711B (zh) 2024-06-01
CN112423789A (zh) 2021-02-26
MX2020006650A (es) 2020-11-06
JP2024001204A (ja) 2024-01-09
AU2018282466A1 (en) 2019-07-11
TW201940162A (zh) 2019-10-16

Similar Documents

Publication Publication Date Title
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2019012884A (es) Terapia de combinacion.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2024010140A (es) Nuevos metodos.
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
PH12017500392A1 (en) Medical treatments based on anamorelin
MY193963A (en) Composition for treating joint diseases and kit containing same
EA201592058A1 (ru) Применение ландиолола гидрохлорида в длительном лечении тахиаритмии
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
UA111312C2 (uk) Спосіб лікування гострого коронарного синдрому без елевації сегмента st у пацієнтів з ішемічною хворобою серця та метаболічним синдромом, що перенесли перкутанну транслюмінарну коронарну ангіопластику
UA115063U (xx) Спосіб лікування собак із больовим синдромом при панкреатиті
EA202191612A1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
ZA202102913B (en) Dosage regime
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
AR109102A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
UA95104U (uk) Спосіб терапії хворих на негоспітальну пневмонію з супутньою хсн